N@N

GKK, GPRO, PYK, JRJC, IMGN, NKTR Are Seasonally Ripe To Go Down In the Next Five Weeks

June 5, 2012 / M2 PRESSWIRE / BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of GRAMERCY CAPITAL CORP (NYSE:GKK), GEN-PROBE INC. (NASDAQ:GPRO), Merrill Lynch Depositor Inc. PPLUS 6.25% Trust Certificates Series GSC (NYSE:PYK), CHINA FINANCE ONLINE CO-ADR (NASDAQ:JRJC), IMMUNOGEN INC (NASDAQ:IMGN), NEKTAR THERAPEUTICS (NASDAQ:NKTR) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: http://www.squeezetrigger.com/services/strat/mh.php

The following stocks are expected to go Down:

  Symbol  Company                          Expected Return  Odds                 By The Following Date
  GKK     GRAMERCY CAPITAL CORP            -2.46%           85.71% (6 of 7)      Wednesday, June 6th 2012
  GPRO    GEN-PROBE INC.                   -2.99%           88.89% (8 of 9)      Monday, June 11th 2012
  PYK     Merrill Lynch Depositor Inc. PPLUS 6.25% Trust Certificates Series GSC  -2.70%           87.50% (7 of 8)      Wednesday, June 13th 2012
  JRJC    CHINA FINANCE ONLINE CO-ADR      -12.25%          85.71% (6 of 7)      Thursday, June 28th 2012
  IMGN    IMMUNOGEN INC                    -4.03%           75.00% (9 of 12)     Thursday, June 7th 2012
  NKTR    NEKTAR THERAPEUTICS              -3.37%           75.00% (9 of 12)     Thursday, June 7th 2012

GRAMERCY CAPITAL CORP (NYSE:GKK) - Gramercy Capital Corp. is a real estate investment trust specializing in the origination and acquisition of first mortgage loans; subordinate interests in whole loans (B Notes); mezzanine financing; preferred equity; bridge loans; and permanent loans. The firm provides its services to public and private property owners, financial institutions, mortgage brokers, and other intermediaries. It also provides financial solutions to borrowers seeking to acquire properties; refinance existing property investments; and fund property renovations or repositioning in all major geographic markets and all property types, including office, retail, apartments, industrial, hotel, and select categories of special-purpose real estate. Additionally, the firm also seeks to acquire distressed debt; mortgage backed securities; and real estate investments. It invests up to $100 million in transitional mortgage loans; up to $75 million in B Notes and mezzanine loans; and up to $50 million in preferred equity investments in CBD and suburban office, neighborhood and community retail, apartments, industrial, lodging, and residential conversions across all major U.S. markets. It may also consider opportunistic investments in sub-performing and non-performing loans; note purchase financings; net lease investments; and other special situations. Gramercy Capital Corp. was founded in April 2004 and is based in New York City with an additional office in Los Angeles, California.

GEN-PROBE INC. (NASDAQ:GPRO) - Gen-Probe Incorporated engages in the development, manufacture, and marketing of nucleic acid tests used primarily to diagnose human diseases and screen donated human blood in North America and internationally. The company markets a portfolio of products to detect infectious microorganisms, including those causing sexually transmitted diseases, tuberculosis, strep throat, and other infections. Its primarily product line includes APTIMA Combo 2 assay, APTIMA CT, APTIMA GC assays, and PACE family of assays to detect chlamydia and gonorrhea; APTIMA Trichomonas ASRs to detect trichomonas; APTIMA HPV assay to detect 14 sub-types of high-risk HPV associated with cervical cancer; and AccuProbe Group B Streptococcus (GBS) assay to detect GBS from culture. The companys product line also include APTIMA HIV-1 assay to detect RNA from HIV-1, the virus that causes AIDS; APTIMA HCV assay to detect RNA from the hepatitis C virus; and ASRs for quantitative HCV testing to quantify HCV viral load. It also offers Pro-Flu+, Pro-Flu ST, ProGastro Cd, AMPLIFIED MTD, and GAS Direct for various respiratory infectious diseases; LIFECODES HLA DNA typing kits and LIFECODES LifeScreen antibody screening kits in the transplant diagnostics field; Procleix HIV-1/HCV assay, Procleix Ultrio assay, Procleix Ultrio Plus assay, and Procleix WNV assay for the blood donor screening market; and TIGRIS and Direct Tube Sampling instrument systems to develop instrumentation. In addition, the companys developing products include PANTHER, an automated testing instrument. Further, the company offers PROGENSA PCA3 and PCA3 ASRs to detect the PCA3 gene. The companys customers include reference laboratories, public health institutions, and hospitals. It has a collaboration agreement with Novartis Vaccines and Diagnostics, Inc. for the research, development, and manufacturing of its blood screening products. The company was founded in 1983 and is headquartered in San Diego, California.

Merrill Lynch Depositor Inc. PPLUS 6.25% Trust Certificates Series GSC (NYSE:PYK) - Merrill Lynch Depositor Inc. PPLUS 6.25% Trust Certificates Series GSC

CHINA FINANCE ONLINE CO-ADR (NASDAQ:JRJC) - China Finance Online Co. Limited provides online financial and listed company data and information in the Peoples Republic of China. The company provides various subscription-based services on a single information platform that integrates data and information from multiple sources with features and functions, such as data and information search, retrieval, delivery, storage, and analysis. It collects, processes, and provides financial analysis tools, historical data, news, research reports, and online forums to its subscribers in one integrated information platform, which allows them to make informed investment decisions with respect to various listed company stocks, bonds, mutual funds, and stock index futures. The companys Website content and research tools also offer various services consisting of attracting visitors and market its subscription based service offerings; storing content and serving as an integral part of its information platform; serving as download platforms for its service offerings; and displaying online advertisements. In addition, its financial analysis tools provide securities market data, technical analysis, and fundamental analysis. Further, the company offers various brokerage and online advertisement services. It serves individual investors managing their own money; professional investors, such as institutional investors managing money on behalf of their clients and high net worth individuals; and other financial professionals, including investment bankers, stock analysts and financial reporters, and middle class individuals. The company markets service offerings through its Websites, jrj.com and stockstar.com, as well as through customer support personnel at its telemarketing and customer service centers. It has strategic alliances with China Telecom and China Center for Financial Research of Tsinghua University. The company was founded in 1998 and is based in Beijing, the Peoples Republic of China.

IMMUNOGEN INC (NASDAQ:IMGN) - ImmunoGen, Inc. engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops its product candidates using its Targeted Antibody Payload (TAP) technology. Its products include Trastuzumab-DM1, a Phase III clinical trial product for the treatment of advanced HER2+ breast cancer; lorvotuzumab mertansine (IMGN901), a Phase I clinical trial product to treat various tumor types, including small-cell lung cancer, ovarian cancer, Merkel cell carcinoma, and the liquid tumor, multiple myeloma; SAR3419, a Phase I clinical trial product for the treatment of non-Hodgkin's lymphoma and other B-cell malignancies; and IMGN388 and BIIB015, which are in Phase I clinical trials for the treatment of solid tumors. The companys products also comprise BT-062, a Phase I clinical trial product targeting multiple myeloma; SAR650984, a Phase I clinical trial product to treat hematological malignancies; SAR566658, a preclinical trail product for the treatment of breast, ovarian, and other solid tumors; and TAP and other compounds. It has collaboration agreements with Amgen, Inc.; Bayer Schering Pharma AG; Biogen Idec MA Inc.; Biotest AG; Genentech, Inc.; Novartis Institutes for BioMedical Research, Inc.; and sanofi-aventis U.S. LLC. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

NEKTAR THERAPEUTICS (NASDAQ:NKTR) - Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. The companys product pipeline consists of drug candidates across various therapeutic areas, including oncology, pain, anti-infectives, anti-viral, and immunology. Its research and development activities involve small molecule drugs, peptides, and other potential biologic drug candidates. The companys proprietary drug candidates in clinical development comprise NKTR-118, a peripheral opioid antagonist, which has completed Phase II clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase II clinical trail to treat gram-negative pneumonias; NKTR-102, a topoisomerase I inhibitor-polymer conjugate, which is in Phase II clinical trail for multiple cancer indications, including breast, ovarian, and colorectal; and NKTR-105 that is in Phase I clinical trail to treat solid tumors. Its preclinical products consists of NKTR-119 (Opioid/NKTR-118 combinations) for the treatment of pain; NKTR-181 (abuse deterrent, tamper-resistant opioid) to treat pain; NKTR-194 (non-scheduled opioid) for the treatment of mild to moderate pain; NKTR-171 (tricyclic antidepressant) to treat neuropathic pain; and NKTR-140 (protease inhibitor candidate) to treat HIV. The company has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. In addition, Nektar Therapeutics has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, Baxter, Roche, Merck, Pfizer, and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.

SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com

www.squeezetrigger.com monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO.

INVESTMENTS & TRADING

SqueezeTrigger -- 25 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

About SQUEEZETRIGGER.COM

WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades.

SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha'a"s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin.

All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion.

Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor.

By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State.

Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind.

Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC.

Contact: Thomas Ronk, CEO www.squeezetrigger.com +1-800-715-9999 Tom@squeezetrigger.com

SqueezeTrigger is a registered trademark, Reg. No. 3,120,641